An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol

Autor: VAN SCHIE, R.M.F., BABAJEFF, A.M.V., SCHALEKAMP, T., WESSELS, J.A.M., LE CESSIE, S., de BOER, A., VAN DER MEER, F.J.M., VAN MEEGEN, E., VERHOEF, T.I., ROSENDAAL, F.R., MAITLAND‐VAN DER ZEE, A.H. ^*

Publikováno v: In Journal of Thrombosis and Haemostasis May 2012 10(5):767-772

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

Autor: Schie, R.M.F. van, Wessels, J.A.M., Cessie, S. le, Boer, A. de, Schalekamp, T., Meer, F.J.M. van der, Verhoef, T.I., Meegen, E. van, Rosendaal, F.R., Maitland-van der Zee, A.H., EU-PACT Study Grp

Publikováno v: European Heart Journal
European Heart Journal, 32(15), 1909-1917
European Heart Journal; Vol 32

Polymorphisms in CYP2C9 and VKORC1 influence patients' phenprocoumon (PHE) and acenocoumarol (ACE) dose requirements. To provide physicians with tools to estimate the patient's individual dose, we aimed to develop algorithms for PHE and ACE.In two Du

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da416c92b061f0e1aa1b7d507cd75de
https://doi.org/10.1093/eurheartj/ehr116

Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

Autor: Wilffert, B., Swen, J. J., Mulder, H., van Schaik, R. H.N., Nijenhuis, M., Grandia, L., van der Zee, A. H.Maitland, Rongen, G. A., Schalekamp, T., van der Weide, J., De Boer, A., Guchelaar, H. J., Touw, D. J., Deneer, V. H.M.

Publikováno v: Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy, 953-1116
STARTPAGE=953;ENDPAGE=1116;TITLE=Handbook of Personalized Medicine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::94077014c9685ce138e3c99a484a45eb
https://pure.amc.nl/en/publications/implementation-of-pharmacogenetics-in-evidencebased-medicine(69d6c649-562a-4b0e-bbd3-4133e0898256).html

Genetic Variation in GATA-4 Might Affect the Coumarin Maintenance Dose

Autor: Schie, R. van, Wessels, J., Hoorn, L. van, Verhoef, T., Schalekamp, T., Cessie, S. le, Meer, F. van der, Rosendaal, F., Visser, L., Teichert, M., Hofman, A., Buhre, P., Boer, A. de, Maitland-van der Zee, A.H.

Publikováno v: Pharmacoepidemiology and Drug Safety, 21, 199-200

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::609a61c5192db3c0b3ffcd10af74c16f
https://hdl.handle.net/1887/99215

The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon

Autor: Verhoef, TI, Zuurhout, MJL, van Schie, RMF, Redekop, Ken, van der Meer, FJM, le Cessie, S, Schalekamp, T, de Boer, A, Maitland-van der Zee, AH

Publikováno v: British Journal of Clinical Pharmacology, 74(6), 1068-1069. Wiley-Blackwell Publishing Ltd

The response to vitamin K antagonists (VKAs) is determined by many different factors like age, weight, height, vitamin K intake and genetic polymorphisms [1]. The proton pump inhibitors (PPIs) omeprazole and esomeprazole may enhance the effect of VKA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::10c94d1f68b38ae12aca4804abcd41c0
https://pure.eur.nl/en/publications/6293e699-b3ae-4857-8d5b-388ab352484a